Genmab, ADC partner to develop new antibody-drug conjugate to treat cancer
The collaboration will integrate Genmab’s high-affinity fully human antibody targeting CD25, HuMax-TAC, with ADC’s PBD-based warhead and linker technology for the devlopment of new product. Genmab chief executive
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.